These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 23873405

  • 1. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1078-85. PubMed ID: 23873405
    [Abstract] [Full Text] [Related]

  • 2. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH.
    J Med Econ; 2014 Jan 07; 17(1):32-42. PubMed ID: 24028444
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH.
    Pharmacoeconomics; 2017 Apr 07; 35(4):425-438. PubMed ID: 27928760
    [Abstract] [Full Text] [Related]

  • 5. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.
    Dtsch Med Wochenschr; 2010 Mar 07; 135(9):385-9. PubMed ID: 20180162
    [Abstract] [Full Text] [Related]

  • 6. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM.
    J Clin Oncol; 2012 Apr 01; 30(10):1064-71. PubMed ID: 22393098
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH, Lalla A, Barron RL, Dubois RW.
    Clin Ther; 2009 May 01; 31(5):1092-104. PubMed ID: 19539110
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.
    Gynecol Oncol; 2014 Jun 01; 133(3):446-53. PubMed ID: 24657302
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH.
    Value Health; 2009 Jun 01; 12(2):217-25. PubMed ID: 18673353
    [Abstract] [Full Text] [Related]

  • 15. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R.
    BMC Cancer; 2013 Jan 08; 13():11. PubMed ID: 23298389
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK, Wong WW, Trudeau ME, Chan KK.
    Breast Cancer Res Treat; 2015 Feb 08; 150(1):169-80. PubMed ID: 25694355
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G.
    Am J Clin Oncol; 2012 Jun 08; 35(3):267-74. PubMed ID: 21378538
    [Abstract] [Full Text] [Related]

  • 18. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
    Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, Chan A.
    PLoS One; 2016 Jun 08; 11(2):e0148901. PubMed ID: 26871584
    [Abstract] [Full Text] [Related]

  • 19. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G.
    Clin Ther; 2009 May 08; 31(5):1069-81. PubMed ID: 19539108
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
    Gebremariam GT, Fentie AM, Beyene K, Sander B, Gebretekle GB.
    BMC Health Serv Res; 2022 Dec 30; 22(1):1600. PubMed ID: 36585648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.